

# Index

## A

- AAV. *See* Adeno-associated virus
- Aberrant network activities, 157–159
- Acetylcholinesterase inhibitor, 32
- Adaptive immunity
  - aging and immunosenescence, 422–423
  - antigen-specificity of T-cell responses, 421–422
  - central and peripheral T cells, 418–421
  - emerging immunotherapy approaches, 423–424
  - innate immunity bridge, 444–446
  - review, 417–425
- Adeno-associated virus (AAV)
  - with gene for glutamic acid decarboxylase (AAV2-GAD) gene therapy, 221–222, 228–230
  - in models of Parkinson's disease, 281–282
- Age at onset, impact on progression, 45
- Aging
  - adaptive immunity, 417–418, 422–423
  - autophagy and, 367–368, 372, 374
  - gut physiology, 406–407
  - mitochondria and, 332, 339–340
  - modeling, 320
  - neurodegeneration, 402
  - as risk factor, 282, 309, 361, 406, 417–418, 422
- Akinesia, 199–203. *See also* Bradykinesia
- Alien limb phenomenon, 27
- ALP. *See* Autophagic-lysosomal pathway
- $\alpha$ -Synuclein (AS)
  - aggregation, 108–109, 248
  - in Alzheimer's disease patients, 261–262
  - animal models, 407
  - autophagic-lysosomal dysfunction, 374–375
  - biologic definition of Parkinson's disease and, 263–264
  - cellular and animal Parkinson's disease models, 109–110
  - clinical trials targeting, 119–120
  - degradation, 117
  - differentially expressed with age, 403
  - in enteric nervous system (ENS), 402–406
  - function, 107
  - in glial cytoplasmic inclusions, 248
  - as immunotherapy target, 423–425
  - levels in CSF, 51
  - in Lewy bodies, 105, 247–248, 272
  - lipids and, 353–362
  - membrane interactions, 354–360
  - mitochondria-associated ER membrane (MAM), 358
  - neuropathology link to Parkinson's disease, 105–106
  - O-GlcNAcylation, 111
  - in Parkinson's disease progression, 48
  - pathogenic effects, 111–118
  - pathological functions of ENS synuclein, 405–406
  - phosphorylated  $\alpha$ -synuclein (p- $\alpha$ -syn), 249–255
  - posttranslational modifications (PTMs), 110–111, 248
  - propagation, 300–301
  - propagation of pathological, 249
  - recombinant  $\alpha$ -synuclein preformed fibrils models, 279–280
  - review, 103–120
  - secretion, 107–108
  - seed amplification assays (SAAs), 51, 249–250, 255–263, 409
  - seeding in the gut, 408
  - SNCA gene, 82
  - S129-phosphorylated, 408–409
  - structure, 104, 106–107
  - structure and function of, 248–249
  - sumoylation, 111
  - triplication of, 358, 360–361
  - truncation, 111
  - ubiquitination, 111
- $\alpha$ -Synuclein, pathogenic effects of
  - cytoskeleton, 116–117
  - disease-related conformations, 113
  - ER, Golgi, and vesicular trafficking, 116
  - mitochondria, 115–116
  - nucleus, 114–115
  - on protein degradation systems, 117–118
  - review, 111–118
  - synapse, 112–114
- $\alpha$ -Synuclein biomarkers
  - blood, 259
  - cerebrospinal fluid, 255
  - differentiating Parkinson's disease from disease mimics, 260–262
  - IG tissue samples, 259
  - methods of detection, 249
  - monitoring disease progression, 262–263
  - overview, 118–119, 408–409
  - review, 247–264
  - skin, 249–255, 260
  - successes and pitfalls, 260–264
  - use in prodromal disease, 263
- $\alpha$ -Synuclein inclusions
  - in MSA, 68
  - in Parkinson's disease, 67–68

## Index

- α-Synuclein models of Parkinson's disease
    - PFF, 279–280, 316
    - recombinant, 279–280
    - transgenic, 314–315
  - α-Synuclein pathology
    - detection of, 300–301
    - propagation of, 277–279
  - α-Synuclein posttranslational modifications
    - acetylation, 111
    - nitration, 110
    - phosphorylation, 110
  - Alzheimer's disease, copathology Lewy bodies disease, 261–262
  - Amantadine, 32
  - An Essay on the Shaking Palsy* (Parkinson), 15, 418
  - Animal models of Parkinson's disease
    - α-synuclein PFF models, 316
    - α-synuclein transgenic Parkinson's disease models, 314–315
    - characterization of mouse, 314
    - DJ-1 genetic models, 318–319
    - freezing of gait in parkinsonism, 204–205
    - of gastrointestinal dysfunction in Parkinson's disease, 407–408
    - genetic mouse model techniques, 310–314
    - introduction, 309–310
    - key features, strengths and limitations, 313
    - knockout (KO) models, 313–314, 317–320
    - knowledge gained from, 314–320
    - LRRK2 transgenic Parkinson's disease models, 316–317
    - overview, 109, 310–312
    - Parkin genetic models, 317–318
    - PINK1 genetic models, 318
    - in primates, 271–283
    - refinement and reinvention of, 319–320
    - review, 309–320
    - Tet-off conditional, 311–313
    - toxin-induced, 289–302
    - transgenic mouse models, 310–317
    - virus-induced, 314
  - Anosmia, 17, 20
  - Anti-IgLN5 disease, 27–28
  - Apomorphine, 32
  - Apoptosis, mitochondrial-dependent, 340–343
  - APS. *See* Atypical parkinsonian syndromes
  - ARJP (autosomal-recessive juvenile parkinsonism), 317
  - AS. *See* α-Synuclein (AS)
  - Association, distinction between causation and, 152
  - Assortativity, 221–223, 228
  - Assortativity coefficient, 221
  - Astrocytes, 437–438
  - Astrocytic plaque, 71
  - A53T-mutant α-synuclein, 281–283
  - ATP13A2, 378–379
  - Atypical parkinsonian syndromes (APs)
    - autophagic-lysosomal pathway (ALP) proteins associated with, 379
    - network analysis for differential diagnosis, 217, 223, 225–226
  - Atypical parkinsonism
    - CSF neurofilament light chain as differentiating marker, 20
    - gait impairment, 204
    - historic perspective, 4–5
    - monogenic, 84–85, 89–90
    - TDP-43-related, 72
  - Autoimmune parkinsonism, 27–28
  - Autonomic dysfunction, 17
  - Autophagic-lysosomal pathway (ALP)
    - alterations in Parkinson's disease, 371–374
    - biomarkers, 380
    - dysfunction linked to Parkinson's disease, 374–380
    - endocytosis, 372–373
    - exocytosis, 373–374
    - mechanisms, 368–371
    - overview, 367–368
    - proteostasis, 371–372
    - review, 367–382
    - therapies in Parkinson's disease, 380–381
  - Autophagosomes, 335, 368–369, 371, 378, 381
  - Autophagy. *See also* Autophagic-lysosomal pathway (ALP)
    - chaperone-mediated (CMA), 117–118, 368–372, 374–377, 381
    - macroautophagy, 117, 368–371, 374–378, 381
    - microautophagy, 368, 371
    - mitophagy, 88, 115, 335–336, 338–340, 369, 372, 377–378
  - Autosomal-recessive juvenile parkinsonism (ARJP), 317
- ## B
- Balance abnormalities, 196
  - Banisterine, 11
  - Basal ganglia
    - basal ganglia model, 169, 181–184
    - corticostriatal connections, 185
    - corticosubthalamic connections, 185–186
    - domains, 184–185
    - dyskinesia, 187
    - functional neuroanatomy, 169–187
    - function and dysfunction, 181–187
    - globus pallidus external segment (GPe), 170, 176–178, 187
    - globus pallidus internal segment (GPi), 170, 176–177, 187, 196
    - input nuclei, 170–177
    - intrinsic nuclei, 177
    - motor aspects of Parkinson's disease, 199–201
    - output nuclei, 177
    - parkinsonism syndrome, 186–187
    - pathophysiology, 186–187
    - striatum, 170–177
    - subcortical connections, 186
    - substantia nigra pars compacta (SNc), 170, 179, 182
    - substantia nigra pars reticulata (SNr), 170, 177

- subthalamic nucleus (STN), 170, 177–181, 183, 185–187
  - thalamobasal ganglia loops, 186
  - Basal ganglia model, 169, 181–184
  - Basal ganglia-related nuclei, 170–171
  - Basal ganglia-thalamocortical circuitry, and motor aspects
    - of Parkinson's disease, 196–198
  - BBB (blood–brain barrier), 442–443
  - Benserazide/levodopa, 29
  - $\beta$ -Band oscillations, 200
  - Bioinformatics of Parkinson's disease, 151–164
  - Biomarkers
    - ALP-based, 380
    - $\alpha$ -synuclein (*see*  $\alpha$ -Synuclein biomarkers)
    - blood-based, 51–52
    - cerebrospinal fluid (CSF), 51
    - gut as target for development, 408–409
    - imaging-based, 49–51
    - informatics in discovery of, 159–162
    - as prognostic indicators of Parkinson's disease
      - progression, 48–52
  - Blood-based  $\alpha$ -synuclein seed amplification assays, 259
  - Blood-based biomarkers, 51–52
  - Blood–brain barrier (BBB), 442–443
  - Body-first hypothesis, 400–401
  - Body-first Parkinson's disease, 249, 260
  - Botulinum neurotoxin, 398–399
  - Braak hypothesis, 399–401
  - Braak Parkinson's disease staging scheme, 69–70
  - Bradykinesia
    - changes in basal ganglia firing rates and patterns, 199–201
    - clinical feature, 16, 18
    - cortical involvement, 201–202
    - neuroplasticity, role of, 202–203
    - pathophysiology of, 196, 199–203
  - Brain-first hypothesis, 400–402
  - Brain-first Parkinson's disease, 249, 260
  - Bulgarian therapy, 7
  - Burst firing, synchronous oscillatory patterns of, 200
- C**
- CADD (computer-aided drug design), 164
  - Calcium homeostasis, and mitochondria, 336–337
  - Cannabis*, 9, 11
  - Carbidopa/levodopa (CD/LD), 29, 32
  - CAR-Tregs (chimeric antigen receptor regulatory T cells), 425
  - Catechol-*O*-methyltransferase (COMT) inhibitors, 29, 32
  - Causation, distinction between association and, 152
  - CBD. *See* Corticobasal degeneration
  - CBS (corticobasal syndrome), 27
  - CD4<sup>+</sup> T cells, 339, 417–418, 420–424
  - CD8<sup>+</sup> T cells, 339, 417–418, 420–424
  - Cell–cell interactions, 443–444
  - Cellular models of Parkinson's disease, 109
  - Central nervous system (CNS), under homeostatic and disease conditions, 434–435
  - Cerebrospinal fluid (CSF)
    - $\alpha$ -synuclein levels, 51, 118–119
    - $\alpha$ -synuclein SAA studies, 119, 255–259
    - biomarkers, 51
      - for Parkinson's disease diagnosis, 20
  - CGG repeats, 27
  - Chaperone-mediated autophagy (CMA), 117–118, 368–372, 374–377, 381
  - Characteristic path length, 221
  - Charcot, Jean-Martin, 1–9, 11–12, 15
  - CHCHD2* gene, 87
  - Chimeric antigen receptor regulatory T cells (CAR-Tregs), 425
  - Chronic traumatic encephalopathy (CTE), 71–72
  - Chronobiological disturbances, MPTP-induced, 275
  - Cilia
    - loss and LRRK2, 139–141
    - signaling in nigrostriatal circuit, 141–142
  - Clarke, Robert Henry, 10
  - Clinical features of Parkinson's disease, 15–18, 65–66
  - Clinical management of Parkinson's disease, 15–35
  - Clinical trials
    - dopamine cell-based replacement therapies, 236–246
      - Earlier versus Later Levodopa (ELLDOPA) trial, 43
      - PARK-*GBA1*, 91–93
      - PARK-*LRRK2*, 92, 94
      - targeting  $\alpha$ -synuclein in Parkinson's disease, 119–120
  - Clustering coefficient, 220
  - CMA (chaperone-mediated autophagy), 117–118, 368–372, 374–377, 381
  - Cognitive impairment, MPTP-induced, 274
  - Cogwheel rigidity, 16, 18
  - Coiled-coil-helix-coiled-coil-helix domain containing 2 (*CHCHD2*) protein, 87
  - Common disease-common variant hypothesis, 152–153
  - Common disease-rare variant hypothesis, 152–153
  - Complement system, 440–441
  - Complex disease
    - dissecting the genetics of, 153–156
    - Mendelian versus, 152–153
  - Complex I blockade, 329
  - Computer-aided drug design (CADD), 164
  - COMT (catechol-*O*-methyltransferase) inhibitors, 29, 32
  - Connectivity and network metrics, 220–222
  - Constipation, 17, 19, 398–399
  - Corticobasal degeneration (CBD)
    - biomarker differentiation from Parkinson's disease, 261
    - network analysis for differential diagnosis, 223
    - overview, 70–71
    - phenotypes, 27
    - radiographic findings, 24
  - Corticobasal syndrome (CBS), 27
  - Corticostriatal connections, 185
  - Corticostriatal pathway, 174
  - Corticosubthalamic connections, 185–186
  - COVID-19, 6
  - CSF. *See* Cerebrospinal fluid

## Index

CTE (chronic traumatic encephalopathy), 71–72  
Cytoskeleton, pathogenic effects of  $\alpha$ -synuclein on,  
116–117

### D

Damage-associated molecular patterns (DAMPs),  
431, 435–436, 438  
Data mining, 161  
DATATOP (deprenyl and tocopherol anti-oxidative therapy  
of parkinsonism), 43  
DAT-SPECT (dopamine transporter imaging using single-  
photon emission tomography), 19, 49, 247,  
255, 263  
Deep brain stimulation (DBS), 34, 44, 205  
Default mode network (DMN), 218, 220, 226  
Degree centrality, 220  
Dementia with Lewy bodies (DLB)  
CSF  $\alpha$ -synuclein, 255, 260  
disease mimics, 260–261  
features, 25–26  
neuropathologic findings, 105  
prodromal, 227  
progression, 227–228  
radiographic findings, 21–22  
rapid eye movement sleep behavior disorder (RBD),  
227–228  
Dendritic cells (DCs), 439  
Deprenyl and tocopherol anti-oxidative therapy of  
parkinsonism (DATATOP), 43  
Diagnosis, early, 226  
Diagnosis of Parkinson's disease, 18–20  
Differential diagnosis  
network analysis, use of, 223, 225–226  
neuropathology, 66–67  
overview, 20–28  
Diffusion tensor imaging (DTI), 51  
Dimethyl fumarate (DMF), 423–424  
Direct reprogramming, 241–242  
DJ-1 genetic models, 318–319  
DLB. *See* Dementia with Lewy bodies  
DMN (default mode network), 218, 220, 226  
DNA, mitochondrial, 331–332  
Domperidone, 398  
Dopamine  
basal ganglia function, 169–171  
historical perspective on therapy, 9–10  
motor signs, role in, 197–198  
quantification of content in striatum, 299–300  
Dopamine cell-based replacement therapies  
direct reprogramming, 241–242  
first clinical trials, 237  
history of, 236–240  
human fVM tissue (hfVM) trials, 237–240  
NIH-funded double-blind placebo-controlled trials,  
237–239  
review, 235–246  
scientific rationale and preclinical evidence, 236–237

stem cell-derived dopaminergic neurons, 240–241,  
245–246  
TransEuro, 239–240, 245  
Dopamine loss, and motor aspects of Parkinson's disease,  
198–199  
Dopamine receptors, in basal ganglia, 171, 173–177, 181,  
184, 187  
Dopamine transporter imaging using single-photon  
emission tomography (DAT-SPECT), 19, 49,  
247, 255, 263  
Dopaminergic neurons  
quantification in substantia nigra par compacta, 298  
stem cell-derived, 240–241, 245–246  
DRP1 (dynamin-related protein I), 333  
Drug discovery  
ligand-based, 163  
rational (RDD), 162  
target-based, 163  
translating genomics into therapeutics, 162–164  
DTI (diffusion tensor imaging), 51  
Dual-hit hypothesis, 400–401  
Dual syndrome hypothesis, 220  
Dynamin-related protein I (DRP1), 333  
Dyskinesia  
graft-induced (GIDs), 237, 239–240  
levodopa-induced dyskinesia (LID), 16, 48, 142,  
235, 271  
MPTP-induced, 275–276  
pathophysiology of, 187  
wearing-off phenomenon, 16, 48, 394  
Dysphagia, 396–398  
Dystonia, 16–17, 19

### E

Earlier versus Later Levodopa (ELLDOPA) trial, 43  
EDS (excessive daytime sleepiness), MPTP-induced, 275  
Electrophysiologic abnormalities in Parkinson's disease,  
200–201  
Endocytosis, 372–373  
Endoplasmic reticulum (ER)  
 $\alpha$ -synuclein effects on, 116  
mitochondrial-associated ER membranes (MAMs),  
337–339, 358–360, 362  
Endosymbiotic theory, 326  
Entacapone, 32  
Enteric nervous system (ENS)  
 $\alpha$ -synuclein (AS) in, 402–406  
neuroanatomy, 394–399  
neurodegeneration in, 402  
Epithelial barriers, 441–442  
Ergot, 7  
ER stress, 372  
*Essay on the Shaking Palsy* (Parkinson), 2  
Essential tremor (ET), 25  
Etiologic models, 280–283  
Excessive daytime sleepiness (EDS), MPTP-induced, 275  
Exocytosis, 373–374

- External pallidal segment (GPe), motor aspects of Parkinson's disease, 196
- External segment of the globus pallidus (GPe), 170, 176–177, 187
- Extracellular vesicles (EVs), 107, 119, 259, 263
- Eye movements, 18–19
- F**
- Familial Parkinson's disease, models of, 280–283
- Fast-spiking interneurons (FSIs), 172
- FDG PET studies of PDRP, 49, 222, 225, 229
- Festination, 16
- Fetal ventral mesencephalon (fVM), use in clinical trials, 237–239
- Floorplate protocols, 240–241
- Fluorodopa, 19, 49
- Focused ultrasound (FUS), 34
- Fragile X tremor/ataxia syndrome (FXTAS), 24, 27
- Freezing, 17
- Freezing of gait (FOG)
- features, 196
  - MPTP-induced, 275
  - pathophysiology of, 204–205
  - treatment response, 205
- Frontotemporal lobar degeneration (FTLD), 72
- FSIs (fast-spiking interneurons), 172
- Functional neuroimaging in Parkinson's disease, 217–230
- G**
- Gait impairment
- clinical features, 16
  - features, 196
  - MPTP-induced, 275
- $\gamma$ -Band oscillatory activities, 200
- Ganglia, enteric, 396
- Gastrointestinal dysfunction in Parkinson's disease
- animal models, 407–408
  - constipation, 398–399
  - dysphagia, 396–398
  - gastroparesis, 398
  - pathophysiology, 399–402
  - review, 393–409
  - symptoms, 394, 396–399
  - systemic manifestations and treatment, 399
- Gastroparesis, 398
- Gaucher's disease (GD), 90, 375, 381
- GBA and ALP dysfunction, 375–377
- GBA1*
- $\alpha$ -synuclein in cerebrospinal fluid, 255, 259
  - $\alpha$ -synuclein deposition in the skin, 251
  - convergent pathway to Parkinson's disease, 144–145
  - genetic risk factor for Parkinson's disease, 28, 90, 144 in PARK-*GBA1*, 90–92
  - progression of Parkinson's disease, 46
- GCase (glucocerebrosidase), 28, 90–92, 338, 353, 375
- GCI (glial cytoplasmic inclusions), 64, 68–69, 248
- GDNF (glial cell-derived neurotrophic factor), 141
- GDP dissociation inhibitors (GDIs), 136–137
- GEFs (guanine nucleotide exchange factors), 136–137
- Genetic parkinsonism, 28–31
- Genetics
- $\alpha$ -synuclein in cerebrospinal fluid, 255, 259
  - $\alpha$ -synuclein deposition in the skin, variation in, 251, 255
  - immune system-associated, 419
  - innate immune system, 433
  - Mendelian versus complex disease, 152–153
  - network analysis of genotype effect, 222–223
  - overview of the genetic loci implicated in the pathogenesis of Parkinson's disease, 154
- Genetics of Parkinson's disease. *See also specific genes*
- atypical monogenic parkinsonism, 84–85, 89–90
  - autosomal-dominant forms of Parkinson's disease, 82–87
  - autosomal-recessive forms of Parkinson's disease, 87–89
  - gene-targeted trials and therapies, 91–94
  - genetic variants, interpretation and classification of, 91
  - genotype–phenotype correlation efforts, 80–81
  - monogenic forms of Parkinson's disease, 81–90
  - overview, 79–80, 83–85
  - PARK-*CHCD2*, 87
  - PARK-*GBA1*, 90–93
  - PARK-*LRRK2*, 82–86, 92, 94
  - PARK-*PARK7*, 88–89
  - PARK-*PINK1*, 88
  - PARK-*PRKN*, 87–88
  - PARK-*RAB32*, 87
  - PARK-*SNCA*, 82
  - PARK-*VPS35*, 86–87
  - progression of disease, 46
  - review, 79–94
  - risk factors, 90–91
- Genome-wide association studies (GWASs)
- common disease-common variant hypothesis, 153
  - genetic association of disease with SNPs, 161
  - immune system-Parkinson's disease associations, 418, 421
- Genomics
- challenge of data analysis, 155
  - highlights of key discoveries, 155
  - personalized therapeutics, development of, 163
  - review, 151–164
  - road ahead for, 164
  - translating rational therapeutics, 162–164
- GFAP (glial fibrillary acidic protein), 52
- Ghrelin, 398–399
- GIDs (graft-induced dyskinesias), 237, 239–240
- GI tissue,  $\alpha$ -synuclein seed amplification assay as PD marker, 259
- Glial cell-derived neurotrophic factor (GDNF), 141
- Glial cytoplasmic inclusions (GCIs), 64, 68–69, 248
- Glial fibrillary acidic protein (GFAP), 52
- Global Parkinson's Genetics Program (GP2)
- Globus pallidus, external segment (GPe), 170, 176–178, 187
- Globus pallidus, internal segment (GPi), 170, 176–177, 187
- Glucocerebrosidase (GCase), 28, 90–92, 338, 353, 375

## Index

- Golgi, 116  
Gowers, William, 2–3, 9, 11  
GP2 (Global Parkinson's Genetics Program)  
GPe (globus pallidus, external segment), 170, 176–178, 187  
GPi (globus pallidus, internal segment), 170, 176–177, 187  
Graft-induced dyskinesias (GIDs), 237, 239–240  
Granulocytes, 440  
Graph theory, 220, 222–223  
Guam Parkinson–dementia complex, 72  
Guanine nucleotide exchange factors (GEFs), 136–137  
Gut–brain axis in Parkinson's disease  
    α-synuclein in ENS (enteric nervous system), 402–406  
    animal models of GI dysfunction in Parkinson's disease, 407–408  
    disease biomarker and treatment development, 408–409  
    gastrointestinal pathophysiology in Parkinson's disease, 393–394, 399, 407  
    GI symptoms in Parkinson's disease, 394, 396–399  
    gut microbiome, 406–407  
    neuroanatomy of ENS (enteric nervous system), 394–399  
    review, 393–409  
Gut microbiome, 406–407  
GWASs. *See* Genome-wide association studies
- ## H
- Heritability, missing, 153  
Herpes simplex virus (HSV), 314, 316  
High-performance liquid chromatography (HPLC), 299–300  
History of Parkinson's disease  
    early clinical descriptions, 1–6  
    evolution of treatments, 6–11  
    review, 1–12  
    separating Parkinson's disease from other disorders, 3–6  
Hornykiewicz, Oleh, 9  
Horsley, Victor, 10  
Hot cross bun sign, 26  
HPLC (high-performance liquid chromatography), 299–300  
HSC70 chaperone, 108, 118, 369–371, 374  
HSV (herpes simplex virus), 314, 316  
Hummingbird sign, 26  
Hydrogen hypothesis, 326  
6-Hydroxydopamine (6-OHDA), 290–293  
Hyoscyamine, 7, 9  
Hypomimia, 15–16  
Hypophonia, 15–16  
Hyposmia, α-synuclein biomarkers, 263
- ## I
- ICD (impulse control disorder), 46  
IENFD (intraepidermal nerve fiber density), 250, 260, 262–263  
Imaging-based biomarkers in Parkinson's disease, 49–51  
Imaging of disease-related networks in Parkinson's disease, 217–230  
Immune function, mitochondrial link to, 338–339  
Immune system  
    adaptive (*See* Adaptive immunity)  
    genes associated with Parkinson's disease, 419  
    innate (*See* Innate immunity)  
Immunohistochemistry of skin biopsy, 250–251  
Immunosenescence in Parkinson's disease, 422–423  
Immunotherapy, 423–425  
Impulse control disorder (ICD), 46  
Inflammation, and mitochondria, 338–339  
Informatics  
    bioinformatics of Parkinson's disease, 151–164  
    in biomarker discovery, 159–162  
    overview, 156–157  
Innate immunity  
    adaptive immunity bridge to, 444–446  
    astrocytes, 437–438  
    blood–brain barriers, 442–443  
    cell–cell interactions, 443–444  
    complement system, 440–441  
    dendrite cells, 439  
    epithelium, 441–442  
    genetics, 433  
    granulocytes, 440  
    lymphatic system, 441  
    mast cells, 439–440  
    microglia, 435–438  
    monocyte–macrophages, 438–439  
    natural killer (NK) cells, 439  
    protective barriers, 441–443  
    responsible cells, 433–440  
    review, 431–446  
Internal segment of the globus pallidus (GPi), 170, 176–177, 187, 196  
Interneurons  
    enteric, 396  
    striatal, 172–173  
Intraepidermal nerve fiber density (IENFD), 250, 260, 262–263  
Istradefylline, 32
- ## J
- Jellinger staging scheme for MSA, 70
- ## K
- KO models of Parkinson's disease  
    overview, 313–314  
    parkin, 317–318  
    PINK, 318
- ## L
- LAMP-2A, 117–118, 369–370, 376–377, 380  
L-dopa-induced dyskinesia (LID), 16, 48, 142, 235, 271  
Leucine-rich repeat kinase 2 (LRRK2) protein, 85–86

- Levodopa
    - clinical progression in PD before and after the advent of, 42–44
    - historical perspective, 9–10
    - motor system management, 29
  - Levodopa/carbidopa intestinal gel (LCIG), 32–34
  - Levodopa-induced dyskinesia (LID), 16, 48, 142, 235, 271
  - Levodopa in EARly Parkinson's disease (LEAP) study, 29, 43
  - Levodopa phobia, 29
  - Lewy bodies
    - $\alpha$ -synuclein, 105, 247–248, 272
    - composition, 68
    - cortical, 68
    - microscopic pathology in Parkinson's disease, 67–68
    - pathology, 61–64, 67–69
  - Lewy neurites, 48, 61–64, 105, 247, 272, 353–354
  - LFPs (local field potentials), 186, 200
  - LID (levodopa-induced dyskinesia), 16, 48, 142, 235, 271
  - LIMP-2, 375–376
  - Lipids
    - $\alpha$ -synuclein and, 353–362
    - alterations and pathogenic roles in synucleinopathies, 353–362
    - composition changes, 354
    - mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) and  $\alpha$ -synuclein, 358–360
  - Lipopolysaccharide, 297–298
  - Local field potentials (LFPs), 186, 200
  - LROs (lysosome-related organelles), 142
  - LRRK2 (leucine-rich repeat kinase 2)
    - ALP dysfunction, 377–378
    - cilia loss, 139–141
    - in convergent pathways to Parkinson's disease, 144–145
    - domain structure, 133–134
    - future studies, 145–146
    - lysosome-related organelle exocytosis, 142–143
    - macrophages, roles in, 143–144
    - mutations, 134–135, 138
    - pathway biochemistry, 140
    - phospho-Rab-specific effectors, 139
    - Rab GTPases as substrates, 135–137
    - reversal of action by PPM family phosphatases, 137–138
    - review, 133–146
    - roles, cell-type-specific, 139–144
    - Shh signaling in nigrostriatal circuit, 141–142, 144–145
  - LRRK2 gene
    - $\alpha$ -synuclein in cerebrospinal fluid, 255, 259
    - autosomal-dominant Parkinson's disease, 82–86, 92, 94
    - clinical trials in PARK-LRRK2, 92
    - PARK-LRRK2, 28, 82–86, 92, 94
  - Lymphatic system, 441
  - Lysosomal storage disease (LSD), 379
  - Lysosome-related organelles (LROs), 142
  - Lysosomes. *See also* Autophagic-lysosomal pathway (ALP)
    - acid hydrolases in, 368
    - autophagy, 367–382
    - LRRK2 recruitment to, 137, 139, 143, 145, 377
    - mitochondrial turnover, 335
    - phospho-Rab accumulation at damaged, 144
- ## M
- Machine learning, 159, 161, 226, 278
  - Macroautophagy, 117, 368–371, 374–378, 381
  - Macrophages
    - innate immunity, 438–439
    - LRRK2 roles in, 143–144
  - Magnetic resonance imaging (MRI)
    - biomarkers of Parkinson's disease progression, 51
    - MCP sign, 27
    - PD diagnosis, 19
  - MAM (mitochondrial-associated ER membranes), 337–339, 358–360, 362
  - Management of Parkinson's disease
    - advanced therapies, 32, 34
    - motor symptoms, 29, 32–33
    - nonmotor symptoms, 32–33
    - review, 29–34
  - MAPS (misfolding-associated protein secretion), 108
  - Masked face, 15, 18
  - Mast cells, 439–440
  - MCP (middle cerebellar peduncles) sign, 27
  - MDR (multifactor dimensionality reduction), 161
  - MDS (Movement Disorder Society), 18
  - MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), 19–20, 42, 45, 262
  - Medium-sized spiny neurons (MSNs), 170–178, 181, 184–185
  - Mendelian diseases, 152
  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *See* MPTP
  - MFN2, 338
  - Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) project, 81
  - Mickey Mouse sign, 26
  - Microautophagy, 368, 371
  - Microbiome, gut, 406–407
  - Microglia, innate immunity, 435–437
  - Middle cerebellar peduncles (MCP sign), 27
  - Misfolding-associated protein secretion (MAPS), 108
  - Mitochondria
    - aging, 339–340
    - bioenergetics, 327
    - calcium homeostasis, 336–337
    - complex I blockage, 329–330
    - DNA, 331–332
    - dynamics, 332–336
    - dysfunction in  $\alpha$ -synuclein transgenic mice, 315
    - fusion and fission, 332–333
    - inflammation, 338–339
    - interorganelle communication, 337–338
    - mitotic segregation, 331
    - motility and regional distribution, 333–335
    - origin of, 326
    - overview, 325–326
    - oxidative phosphorylation system, 328–330

## Index

- Mitochondria (*Continued*)  
pathogenic effects of  $\alpha$ -synuclein, 115–116  
programmed cell death, 340–343  
review, 325–343  
structure, 326  
threshold effect, 331  
turnover, 335–336  
uncoupling proteins, 330–331
- Mitochondrial-associated ER membranes (MAMs), 337–339, 358–360, 362
- Mitochondrial hypothesis of Parkinson's disease (PD), 325
- Mitochondrial oxidative phosphorylation system, 328–329
- Mitochondrial quality control (MQC) systems, 339
- Mitochondrial UPR system (UPRmt), 372
- Mitophagy, 88, 115, 335–336, 338–340, 369, 372, 377–378
- Mitotic segregation, 331
- Models of Parkinson's disease  
animal, 109–110, 309–320  
assessments of nigrostriatal dopaminergic structures and function, 298–302  
cellular, 109  
ideal, features of, 290  
in primates, 271–283
- Modularity, 221
- Monkeys, modeling Parkinson's disease in, 271–283
- Monoamine oxidase B inhibitors, 29, 32
- Monocytes, 438–439
- Monounsaturated FAs (MUFAs), 354, 358–361
- Moore's law, 155
- Motor function, assessment of, 301–302
- Motor signs  
basal ganglia firing rates and patterns, 199–201  
basal ganglia-thalamocortical circuitry, 196–198  
bradykinesia, 196, 199–203  
dopamine, role of, 197–198  
dopamine loss, 198–199  
freezing of gait (FOG), 196, 204–205  
management of, 29, 32–33  
neuroplastic changes, 199  
pathophysiology of, 195–206  
progression, 43  
review, 15–17, 195–206  
rigidity, 196, 203  
tremor, 196, 203–204
- Motor triad, after MPTP treatment, 274
- Mouse  
models of Parkinson's disease, 309–320  
toxin-induced models of Parkinson's disease, 289–302
- Movement Disorder Society (MDS), 18, 42
- Movement Disorder Society Genetic Mutation Database (MDSGene), 80–81, 135
- MPTP  
anatomopathology, 272–274  
behavior assessment, 276  
experimental use, 276–277  
historic perspective, 6  
immune system effects, 438–439  
mitochondrial connection, 328–330, 332, 335, 337, 340–341  
mitochondrial effects, 329–330  
models in primates, 272–277  
in models of GI dysfunction, 407  
in mouse models of Parkinson's disease, 315, 317–318, 421  
overview, 293–294  
phenocopy induced by, 274–276  
in primate models of Parkinson's disease, 272–278, 280  
structure, 291  
toxin-induced models of Parkinson's disease, 293–295
- MPTP-induced anatomopathology, 272–274
- MPTP-induced phenocopy  
cognitive impairment, 274  
dyskinesia, 275–276  
gait impairment, 275  
motor triad, 274  
sleep/chronobiological disturbances, 275
- MQC (mitochondrial quality control) systems, 339
- MRI. *See* Magnetic resonance imaging
- MSA. *See* Multiple systems atrophy
- MSNs (medium-sized spiny neurons), 170–178, 181, 184–185
- MUFAs (monounsaturated FAs), 354, 358–361
- Multifactor dimensionality reduction (MDR), 161
- Multiple systems atrophy (MSA)  
atypical monogenic parkinsonism, 89  
biomarker and differentiation from Parkinson's disease, 260–261  
clinical features of, 66  
differential diagnosis, 20, 26  
disease mimics, 260–261  
filamentous  $\alpha$ -synuclein in, 105  
glial cytoplasmic inclusions (GCIs), 64, 68–69, 248  
Jellinger staging scheme for, 70  
lipid composition, 354  
macroscopic pathology, 66–67  
MCP sign, 27  
network analysis for differential diagnosis, 223  
overview, 26  
pathology, 61–68, 70  
PDRP, 223, 227–228  
phosphorylated  $\alpha$ -synuclein in, 110, 250, 252–254, 260  
radiographic findings, 23
- Myosin Va (MyoVa), 139
- ## N
- Natural killer (NK) cells, 439
- Network activities, identification of aberrant, 157–159
- Network analysis  
applications, 222–230  
graph theory, 220, 222–223  
network metrics, 220–222  
Parkinson's disease cognition-related pattern, 218, 220  
Parkinson's disease motor-related pattern, 218–219

Network analysis applications  
  differential diagnosis, 223, 225–226  
  disease progression, 226–228  
  early diagnosis, 226  
  genotypic effect, 222–223  
  prodromal Parkinson's disease, 226–228  
  treatment-induced networks and the placebo response,  
    228–230

Network assortativity, 221, 223

Networks, treatments-induced, 228–230

Neuroanatomy of enteric nervous system (ENS),  
  394–399

Neurofibrillary tangles, 65, 68, 70, 72

Neurofilament light chain (NFL), 52

Neuroimaging in Parkinson's disease, functional,  
  217–230

Neuromelanin, 62–65, 69, 71, 179, 273, 282, 381, 438

Neuronal synuclein disease international staging system  
  (NSD-ISS), 263

Neurons, enteric, 396

Neuropathology, 61–63. *See also* Pathology

Neuroplastic changes in Parkinson's disease, 199

Neuroplasticity, role in motor abnormalities, 202–203

Neurotoxin. *See* MPTP

Neurturin (NRTN), 141

Nfl (neurofilament light chain), 52

Nigrostriatal dopaminergic structure and function,  
  assessments of, 298–302

Nigrostriatal pathway  
  ciliary signaling in the, 141–142, 144–145  
  loss of dopaminergic neurons, 235  
  overview, 175–176

NK (natural killer) cells, 439

*N*-methyl-D-aspartate receptor (NMDAR) antagonist, 32

Nonhuman primate (NHP) models of Parkinson's disease,  
  271–283

Nonmotor signs  
  gastrointestinal, 394, 396–399  
  management of, 32  
  progression, 43–44  
  review, 17

Normal pressure hydrocephalus (NPH), 261

NRTN (Neurturin), 141

NSD-ISS (neuronal synuclein disease international staging  
  system), 263

Nucleus,  $\alpha$ -synuclein effects on, 114–115

**O**

Olfactory epithelium,  $\alpha$ -synuclein seed amplification assay  
  in, 259–260

Olfactory loss, 17, 20

Oligodendrocytes, glial cytoplasmic inclusions of  
   $\alpha$ -synuclein in, 248

-Omics, 156–161

Opicapone, 32

Optic atrophy I (OPAI), 333

Outer membrane permeabilization, 341–343

**P**

PAMPs (pathogen-associated molecular patterns), 431,  
  435–436, 438

Paraquat, 291, 294–296

PARIS, 319–320, 340

*PARK7*, 79, 81–82, 88–89, 338, 433

*PARK-CHCHD2*, 87

*PARK-GBA1*  
  clinical trials in, 91–93  
  overview, 90

Parkin  
  ALP dysfunction, 377–378  
  genetic models, 317–318  
  *PARK-PRKN*, 87–88

Parkin-interacting substrate (PARIS), 319–320, 340

Parkinson, James, 1–3, 6, 15, 394, 418

Parkinson dementia complex (PDC), 72

Parkinsonism  
  atypical (*see* Atypical parkinsonism)  
  basal ganglia, 186–187  
  degenerative, 19, 62  
  drug-induced, 25  
  neuropathology of, 66–73  
  nondegenerative, 62  
  TDP-43-related, 72–73  
  vascular, 65

Parkinsonism-plus, 1, 3–4, 64, 70

Parkinson's disease (PD)  
  adaptive immunity, 417–425  
   $\alpha$ -synuclein biomarkers, 247–264  
  animal models, 309–320  
  autophagy and protein quality control, 367–382  
  biological definition of, 263  
  clinical management, 15–35  
  defining, 1–3  
  genetics, 79–94  
  genomics and bioinformatics, 151–164  
  gut–brain, 393–409  
  historical perspectives of, 1–12  
  imaging of disease-related networks, 217–230  
  innate immunity, 431–446  
  mitochondrial connection, 325–343  
  modeling in primates, 271–283  
  neuropathology, 61–73  
  pathophysiology of motor control abnormalities,  
    195–206  
  progression in, 41–52  
  toxin-induced animal models, 289–302

Parkinson's disease cognition-related pattern (PDCP),  
  49–50, 217–218, 220, 222–223, 226–229

Parkinson's disease dementia, 25

Parkinson's disease GENeration, 81

Parkinson's Disease Progression Markers Initiative  
  (PPMI), 45

Parkinson's disease-related cognitive pattern (PDCP),  
  49–50

Parkinson's disease-related pattern (PDRP), 49–50, 217–229

Parkinson's disease-related tremor pattern (PDTP), 229

## Index

- Parkinson's Progression Markers Initiative (PPMI), 45, 49, 255
- PARK-PARK7, 88–89
- PARK-PINK1, 88
- PARK-PRKN, 87–88
- PARK-RAB32, 87
- PARK-SNCA, 82
- PARK-VPS35, 86–87
- PARP1, 315
- Pathogen-associated molecular patterns (PAMPs), 431, 435–436, 438
- Pathogenic models of Parkinson's disease, 277–280
- Pathology
  - Braak Parkinson's disease staging scheme, 69–70
  - chronic traumatic encephalopathy (CTE), 71–72
  - corticobasal degeneration (CBD), 70–71
  - distribution of, 69
  - Guam Parkinson–dementia complex (PDC), 72
  - Jellinger staging scheme for MSA, 70
  - macroscopic, 66–67
  - microscopic, 67–70
  - multiple system atrophy (MSA), 61–68, 70
  - overview, 61–65
  - Parkinson's disease (PD), 61–73
  - progressive supranuclear palsy (PSP), 61, 63–71
  - review, 61–73
  - TDP-43-related parkinsonism, 72–73
- Pathophysiology
  - basal ganglia, 186–187
  - gastrointestinal, 399–402
  - of motor control abnormalities in Parkinson's disease, 195–206
- Patient-derived brain extract models, 277–279
- PCD (programmed cell death), mitochondria and, 340–343
- PD. *See* Parkinson's disease
- PDC (Parkinson dementia complex), 72
- PDCP (Parkinson's disease cognition-related pattern), 49–50, 217–218, 220, 222–223, 226–229
- PDRP (Parkinson's disease-related pattern), 49–50, 217–229
- PDTP (Parkinson's disease-related tremor pattern), 229
- Pedunculopontine nucleus (PPN), 170, 196, 198, 203–205, 272
- Perry syndrome, 73
- PET imaging, 19, 49–50, 222, 225, 229
- PF (preformed fibril) injections,  $\alpha$ -synuclein, 309, 315
- Pharmacophore, 163
- Phenocopic models of Parkinson's disease, 274–276
- Phenocopy, MPTP-induced, 274
- PIGD (postural instability and gait disorder) subtype, 45, 51–52
- Pill-rolling phenomenon, 16
- PINK1 gene
  - autosomal-recessive Parkinson's disease, 88
  - convergent pathway to Parkinson's disease, 144–145
  - PARK-PINK1, 88
- PINK1 protein
  - ALP dysfunction, 377–378
  - function, 88
  - genetic models, 318
- Placebo effects
  - network analysis, 229–230
  - therapy, 11
- Place effects, 229
- Plasticity
  - at GABAergic synapses, 199
  - neuroplastic role in motor abnormalities, 202–203
- PMCA (protein misfolding cyclic amplification), 249
- POLG, 340
- POLG mutations, 332
- Polygenic risk scores, 46
- Polyunsaturated FAs (PUFAs), 354, 359
- Positron emission tomography (PET), 19, 49–50, 222, 225, 229
- Postencephalitic parkinsonism
  - historical perspective, 4
  - post-COVID-19 parkinsonism, 6
- Postural instability and gait disorder (PIGD) subtype, 45, 51–52
- Postural symptoms, 16, 196
- PPM family phosphatases, reversal of LRRK2 action by, 137–138
- PPMI (Parkinson's Disease Progression Markers Initiative), 45, 49, 255
- PPN (pedunculopontine nucleus), 170, 196, 198, 203–205, 272
- Preformed fibril (PF) injections,  $\alpha$ -synuclein, 309, 315
- Primates, modeling Parkinson's disease in
  - $\alpha$ -synuclein preformed fibrils models, 279–280
  - etiological models, 280–283
  - familial Parkinson's disease models, 280–283
  - MPTP models, 272–277
  - pathogenic models, 277–280
  - patient-derived brain extract models, 277–279
  - phenocopic models, 272–277
  - review, 271–283
  - synucleinopathy models, 277–280
  - transgenic models, 282–283
  - viral vector-based, 281–282
- PRKN gene
  - $\alpha$ -synuclein deposition in the skin, 251
  - autosomal-recessive Parkinson's disease, 87–88
  - blood-based  $\alpha$ -synuclein seed amplification assays, 259
  - progression of Parkinson's disease, 46
- Procerus sign, 26
- Prodromal disease
  - $\alpha$ -synuclein biomarkers, 263
  - network analysis, 226–228
  - parkinsonism, 17–18
  - symptoms, 17–18, 41
- Programmed cell death (PCD), mitochondria and, 340–343
- Progression in Parkinson's disease
  - $\alpha$ -synuclein, 48
  - $\alpha$ -synuclein biomarkers for monitoring, 262–263
  - before and after advent of levodopa, 42–44
  - biomarkers as prognostic indicators of, 48–52
  - clinical assessment, 42

- clinical factors, 44–46
  - clinical variables, 44–46
  - genetic factors, 46
  - network analysis, 226–228
  - pathological underpinnings, 47–48
  - postsynaptic mechanisms, 47–48
  - presynaptic mechanisms, 47
  - review, 41–52
- Progressive supranuclear palsy (PSP)
- biomarker differentiation from Parkinson's disease, 261
  - clinical features of, 66
  - macroscopic pathology, 66–67
  - network analysis for differential diagnosis, 223
  - neuronal and glial tau pathology in, 68–69
  - pathology, 61, 63–71
- Progressive supranuclear palsy-Richardson syndrome (PSP-RS), 26
- Protective barriers, 441–443
- Protein degradation systems, 117–118
- Protein misfolding cyclic amplification (PMCA), 249
- Protein quality control, 367–382
- Proteomics in biomarker discovery, 161
- Proteostasis in Parkinson's disease, 367–382
- PSP. *See* Progressive supranuclear palsy
- PSP-RS (progressive supranuclear palsy-Richardson syndrome), 26
- Q**
- Quantitative methodologies for SAR (QSAR), 164
- R**
- rAAV (recombinant adeno-associated virus), 314, 316
- RAB32
- autosomal-dominant Parkinson's disease, 87
  - PARK-RAB32, 87
- Rab GTPase
- as LRRK2 substrates, 135–137, 316–317
  - phospho-Rab-specific effectors, 139
  - reversal of LRRK2 action by PPM family phosphatases, 137–138
- Random forests (RFs), 161
- Rapid eye movement sleep behavior disorder (RBD), 17, 227–228, 263
- Rapid eye movement (REM) sleep dysregulation, MPTP-induced, 275
- Rational drug discovery (RDD), 162
- Reactive oxygen species (ROS), 329–330
- Real-time quaking-induced conversion (RT-QuIC)
- assays, 249
- Recombinant adeno-associated virus (rAAV), 314, 316
- Regulatory T (Treg), 418, 420, 422, 425
- Reprogramming, direct, 241–242
- Resting tremor, 16, 18, 196, 203–204
- Rigidity, 16, 18, 196, 203, 274
- RILPL1 and RILPL2, 139
- Risk factors, genetic, 90–91
- RNA, as biomarker, 51–52
- ROS (reactive oxygen species), 329–330
- Rostock Parkinson's Disease (ROPAD) study, 81
- Rotenone, 291, 296–297
- RT-QuIC (real-time quaking-induced conversion)
- assays, 249
- S**
- S15 protein, 317
- Safinamide, 29, 32
- Salivary  $\alpha$ -synuclein seed amplification assay, 260
- SAR (structure–activity relationship), 163–164
- SCD (stearoyl-CoA desaturase), 360–361
- Seed amplification assays (SAAs)
- $\alpha$ -synuclein (AS), 51, 119, 249–250, 255–263, 409
  - CSE, 119, 255–259
  - differentiating between disease types, 261
- Shaking chair, 8
- Sham surgery-related pattern (SSRP), 230
- Shh (sonic hedgehog) signaling in the nigrostriatal circuit, 141–142, 144–145
- Sialorrhea, 397–398
- SIRT1, 340
- Skin
- $\alpha$ -synuclein biomarkers, 249–255, 260
  - biopsy, 19–20, 251
- Sleep disturbances, MPTP-induced, 275
- Small-worldness, 221
- SNARE complex, 107, 112–114, 355, 402
- SNCA
- $\alpha$ -synuclein, 103–105
  - autosomal-dominant Parkinson's disease, 82, 104–105
  - discovery of missense mutations, 153
  - genome-wide association studies (GWAS), 105
  - lipid alteration link, 358
  - PARK-SNCA, 82
  - progression of Parkinson's disease, 46
  - triplication of, 46, 80, 82, 105, 300
- Sniffin Stick Test, 20
- SNPs, 161
- Sonic hedgehog (Shh) signaling in the nigrostriatal circuit, 141–142, 144–145
- SSRP (sham surgery-related pattern), 230
- Stearoyl-CoA desaturase (SCD), 360–361
- STN StimNet, 229
- Striatal neurons, 170–171
- Striatum
- afferent systems, 174–176
  - compartments, 172–174
  - corticostriatal pathway, 174
  - efferent systems, 176–177
  - loss of dopaminergic neurons, 235–236
  - neurons, 170–172
  - nigrostriatal pathway, 175–176
  - quantification of dopamine content, 299–300
  - quantification of dopaminergic terminals in the, 298–299

## Index

- Striatum (*Continued*)  
  striosomes, 172–175, 273  
  thalamostriatal pathway, 174–175  
Striosomes, 172–175, 273  
Structure–activity relationship (SAR), 163–164  
Substantia nigra, loss of dopaminergic neurons in, 235  
Substantia nigra pars compacta (SNc)  
  basal ganglia, 170, 179, 182  
  dopaminergic inputs from, 197  
  Lewy body pathology in, 272  
  loss of dopamine neurons in, 47, 271  
  MPTP effect on, 328  
  quantification of dopaminergic neurons in, 298  
Substantia nigra pars reticulata (SNr)  
  basal ganglia, 170, 177  
  motor aspects of Parkinson's disease, 196  
  striatal input, 177  
Subthalamic nucleus (STN)  
  AAV2-GAD, 221–222, 228–230  
  basal ganglia, 170, 177–181, 183, 185–187  
  hyperdirect pathway, 198  
  motor aspects of Parkinson's disease, 196  
Surgery for PD, historical perspective, 10–11  
Swallowing difficulty, 396–398  
Symptoms. *See also specific symptoms*  
  gastrointestinal, 394, 396–399  
  motor, 15–17, 29, 32–33  
  nonmotor, 17, 32–33  
  postural, 16, 196  
  predominant at onset of disease, 45  
  prodromal, 17–18, 41  
  progression, 41–49  
Synapse,  $\alpha$ -synuclein pathogenic effects at, 112–114  
SynNeurGe classification, 263  
SynOne, 255  
Synucleinopathy  
  diagnosis, 19–20  
  lipids alterations and pathogenic roles in, 353–362  
  models of, 277–280  
  seed amplification assays (SAAs), 249
- ## T
- TANs (tonically active neurons), 172  
Targeted protein degradation (TPD) tools, 381  
Tau pathology  
  biomarker differentiation from Parkinson's disease, 261  
  in progressive supranuclear palsy (PSP), 68–69  
Tau protein as biomarker, 261  
T-cell receptors (TCRs), 418, 420, 422, 424–425  
T cells  
  antigen-specificity of T-cell responses in Parkinson's disease, 421–422  
  CD4<sup>+</sup>, 339, 417–418, 420–424  
  CD8<sup>+</sup>, 339, 417–418, 420–424  
  helper (Th) cells, 339, 418, 420, 422  
  in human and experimental Parkinson's disease, 418–421  
  regulatory T (Treg), 418, 420, 422, 425  
TDP-43, 72–73  
Tet off conditional transgenic models, 311–313  
TFEB (transcription factor EB), 369, 381  
Thalamobasal ganglia loops, 186  
Thalamostriatal pathway, 174–175  
T helper (Th) cells, 339, 418, 420, 422  
Therapy. *See Treatment*  
Threshold effect, 331  
Thyrosine hydrolase (TH), 107, 114, 279–282, 316, 319, 403  
TMEM175, 338, 379  
Tolcapone, 32  
Tonically active neurons (TANs), 172  
Toxin-induced animal models  
  assessments of nigrostriatal dopaminergic structures and function, 298–302  
  6-hydroxydopamine (6-OHDA), 290–293  
  key features, 292  
  lipopolysaccharide, 297–298  
  MPTP, 293–294  
  paraquat, 291, 294–296  
  review, 289–302  
  rotenone, 291, 296–297  
TPD (targeted protein degradation) tools, 381  
Transcription factor EB (TFEB), 369, 381  
Transcriptomics, 49, 151, 155–156, 162, 406, 437  
TransEuro study, 239–240, 245  
Transgenic models in primates, 282–283  
Transgenic mouse models  
   $\alpha$ -synuclein, 314–315  
  overview, 310–311  
  Tet-off conditional, 311–313  
Treatment  
  constipation, 399  
  dopamine cell–based replacement, 235–246  
  dysphagia, 398  
  emerging immunotherapy approaches, 423–425  
  enhancement of the autophagic-lysosomal pathway, 380–381  
  for freezing of gait (FOG), 205  
  gastroparesis, 398  
  gut microbiome impact on, 407  
  translating genomics into rational therapeutics, 162–164  
Treatment, historic  
  hyoscyamine, 7, 9  
  levodopa, 9–10  
  placebo therapy, 11  
  review, 6–11  
  surgery, 10–11  
  suspension, 8–9  
  vibration therapy, 8, 11  
Treatment-induced networks, 228–230  
Treg (regulatory T), 418, 420, 422, 425  
Tremor-dominant subtype, 45

Tremors

- after MPTP treatment, 274
- at rest, 16, 18, 196, 203–204
- essential, 25
- pathophysiology of, 203–204

U

- Ubiquitin-proteasome system (UPS),  
367, 371–372, 374
- Uncoupling proteins, 330–331
- Unfolded protein response (UPR), 372
- Unified Parkinson's Disease Rating Scale (UPDRS), 42–43,  
45, 239–240, 245, 262, 274, 276
- University of Pennsylvania Smell Identification Test  
(UPSIT), 20
- UPRmt (mitochondrial UPR system), 372
- UPS (ubiquitin-proteasome system), 367, 371–372, 374

V

- Vacuolar protein sorting 35 (VPS35) protein,  
86, 433
- Vagus nerve, 69, 105, 396–397, 400, 406–408
- Vascular parkinsonism, 20, 22, 25
- Vesicular traffic, 116
- Vibratory therapy, 8, 11
- Viral vector-based models, 281–283
- Virus-induced models, 314
- VPS35 gene
  - autosomal-dominant Parkinson's disease, 86–87
  - PARK-VPS35, 86–87
- VPS35 protein, 86, 433

W

- Wearing-off phenomenon, 16, 47–48, 275, 394